Biogen International GmbH v. Mylan Pharmaceuticals Inc.
Petition for certiorari denied on October 3, 2022
Issue: Whether 35 U.S.C. § 112"s requirement that a patent specification "contain a written description of the invention" is met when the specification describes the invention, or whether the specification must also disclose data that demonstrates the claimed invention is "effective" and emphasize the claimed invention by singling it out and describing it more than once.
SCOTUSblog Coverage
- Two petitions from North Carolina seek to resolve pay and benefits for public employees (Kalvis Golde, July 4, 2022)
| Date | Proceedings and Orders |
|---|---|
| 06/14/2022 | Petition for a writ of certiorari filed. (Response due July 15, 2022) |
| 06/30/2022 | Motion to extend the time to file a response from July 15, 2022 to August 15, 2022, submitted to The Clerk. |
| 07/01/2022 | Motion to extend the time to file a response is granted and the time is extended to and including August 15, 2022. |
| 07/11/2022 | Brief amicus curiae of Chemistry and the Law Division of the American Chemical Society filed. |
| 07/14/2022 | Brief amicus curiae of New England Legal Foundation filed. |
| 07/15/2022 | Brief amici curiae of Pharmaceutical Research and Manufacturers of America, et al. |
| 08/15/2022 | Brief of respondent Mylan Pharmaceuticals Inc. in opposition filed. |
| 08/30/2022 | Reply of petitioners Biogen International GmbH and Biogen MA Inc. filed. (Distributed) |
| 08/31/2022 | DISTRIBUTED for Conference of 9/28/2022. |
| 10/03/2022 | Petition DENIED. |